Related Experiment Video
Updated: Jun 28, 2026
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
Animal models of polyglutamine diseases and therapeutic approaches
J Lawrence Marsh1, Tamas Lukacsovich, Leslie Michels Thompson
1Developmental Biology Center and the Department of Developmental and Cell Biology, University of California, Irvine, California 92697, USA. jlmarsh@uci.edu
Abstract:
The dominant gain-of-function polyglutamine repeat diseases, in which the initiating mutation is known, allow development of models that recapitulate many aspects of human disease. To the extent that pathology is a consequence of disrupted fundamental cellular activities, one can effectively study strategies to ameliorate or protect against these cellular insults. Model organisms allow one to identify pathways that affect disease onset and progression, to test and screen for pharmacological agents that affect pathogenic processes, and to validate potential targets genetically as well as pharmacologically. Here, we describe polyglutamine repeat diseases that have been modeled in a variety of organisms, including worms, flies, mice, and non-human primates, and discuss examples of how they have broadened the therapeutic landscape.
Insights
Polyglutamine repeat diseases, caused by known mutations, are studied in model organisms. These models help identify therapeutic targets and develop treatments for these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Gain-of-function polyglutamine repeat diseases stem from known mutations.
- Pathology arises from disrupted fundamental cellular activities.
Purpose of the Study:
- To describe polyglutamine repeat diseases modeled in various organisms.
- To discuss how these models have advanced therapeutic strategies.
Main Methods:
- Development of disease models in organisms like worms, flies, mice, and non-human primates.
- Utilizing models to study cellular insults and disease progression.
Main Results:
- Models recapitulate key aspects of human polyglutamine repeat diseases.
- Identification of pathways influencing disease onset and progression.
- Screening and validation of pharmacological agents and therapeutic targets.
Conclusions:
- Model organisms are crucial for understanding and treating polyglutamine repeat diseases.
- These models have significantly expanded the therapeutic landscape for these conditions.
